Hardware Podcasts

226 - Navigating China NMPA Medical Device Requirements | Standards, GMP Updates, Agents & Classification

Let's Combinate · 18 Feb 2026 · 29m

What this episode covers

Elaine (Yi Ling Tan) of MedTech Chopsticks explains that Western manufacturers often fail in China because they assume EU or US approvals (IEC/ISO, FDA) translate directly, whereas China requires compliance with local GB (national) and YY (industry) standards. She details the necessity of local type testing using Product Technical Requirements (PTRs) and highlights that China’s GMP differs from ISO 13485, particularly with upcoming dual market release requirements in November 2026. The conversation covers the critical role of China agents in managing NMPA-designated testing labs, clinical evaluation predicates, and post-market surveillance, noting that misclassification changes every two years can drastically alter regulatory strategy.

Most relevant to

early-stage companies

Topics

Mentioned

Companies
MedTech Chopsticks
Also
NMPA, GB, YY, ISO 13485, IEC 60601, FDA, EU

Related episodes from other shows

Other shows on the same ground, closest first.

  • Global Medical Device Podcast · 40m

    #432: China MedTech Compliance: Regulatory Risks, Rewards, & Strategy with Elaine Tan

    Elaine Tan, creator of MedTech Chopsticks, explains the regulatory and strategic complexities of entering the Chinese medical device market, highlighting the NMPA's 2021 overhaul and the 'China for China' policy. She details the necessity of local type testing, the dual-strategy approach for IP protection, and the critical requirement for agents to hold an NMPA-approved CA USB key for electronic submissions. The discussion covers leveraging the Hainan Free Trade Zone for real-world data collection and the importance of gap analysis against Chinese Product Technical Requirements (PTR).

    Certification & complianceManufacturing partners & offshoring
    9 chapters

  • Global Medical Device Podcast · 48m

    #449: 7 Pitfalls of International MedTech Expansion

    Mike Drues, President of Vascular Sciences, joins host Etienne Nichols to discuss the regulatory pitfalls international medical device companies face when expanding into the U.S. market. Drues challenges the assumption that a CE Mark guarantees FDA clearance, explaining that different labeling or claims technically create different devices, which complicates Quality Management Systems and post-market surveillance. He outlines seven key mistakes, including assuming U.S. standards match international ones, failing to synchronize regulatory and reimbursement strategies early, and unnecessarily repeating clinical trials when outside-the-U.S. data can be leveraged.

    Certification & complianceQuality & yield
    7 chapters

  • Global Medical Device Podcast · 58m

    #404: MedTech 101: What You Need to Know About the Medical Device Industry

    Etienne Nichols hosts Sara Adams and Chris Rush from Greenlight Guru for a foundational overview of the medical device industry. They define medical devices by intended use and labeling, distinguishing roles for Quality, Regulatory, Clinical, and R&D teams. The trio explains FDA classifications (Class I, II, III), regulatory pathways like 510(k) and PMA, and key standards including ISO 13485 and ISO 14971. They emphasize the importance of design controls, risk management, and reading regulations to navigate compliance and market access.

    Certification & complianceValidation & product-market fit
    6 chapters

  • Global Medical Device Podcast · 40m

    Challenges for Regulatory Submission: EU vs. US

    Michelle Lott, Founder of leanRAQA and former FDA DGMPAC member, explains the severe regulatory hurdles of the EU MDR compared to the US FDA pathway, noting that 18,000 MDD certificates were issued but only 1% have transitioned to MDR. She highlights that companies face exorbitant notified body fees, a bottleneck of only 28 notified bodies, and the requirement for ISO 13485 certification, leading many small and large firms to withdraw from the EU market. Lott advises startups to perform a market analysis to determine if their revenue model supports these recurring costs, warning that 'hope is not a regulatory strategy' as certificates expire in May 2024. The discussion covers the shift from a linear US submission process to a continuous, living system in the EU, including annual audits and recertification every three years.

    Certification & complianceStarting a product company
    7 chapters

  • Global Medical Device Podcast · 31m

    Tips to Prepare for EU MDR and IVDR as Deadlines Draw Near

    Bassil Akra, CEO and Co-Owner of QUNIQUE Group, explains the critical challenges medical device companies face in transitioning to EU MDR and IVDR, highlighting the severe bottleneck of notified body capacity and the increased burden of clinical evidence requirements. He clarifies that holding a valid MDD certificate does not buy significant time, as manufacturers must still meet MDR post-market surveillance and vigilance obligations immediately, with full certification required by mid-2023. Akra warns that the IVDR transition is particularly dangerous for the industry because 80-90% of the market will suddenly require notified body involvement, creating a resource gap that existing infrastructure cannot fill. He advises companies to read the regulations, re-evaluate notified body capacity, and manage strict implementation timelines to avoid losing market access.

    Certification & complianceScaling production
    7 chapters

The summary, chapters and topics are generated from the episode’s audio by this directory, not written by Let's Combinate. The episode itself belongs to its publisher.